Allen Clermont

Allen Clermont has extensive work experience in the field of pharmacology, diabetes research, and translational research. Allen currently holds the position of Director of Preclinical Pharmacology at KalVista Pharmaceuticals, Inc. Allen has previously worked as the Associate Director and Principal Scientist - In Vivo Pharmacology and Target Validation at the same company.

Prior to their role at KalVista Pharmaceuticals, Inc., Allen worked at the Joslin Diabetes Center for a significant period. During their time there, they served as the Assistant Physiology Core Director and conducted various research projects related to microvascular complications of diabetes. Allen'sspecialties included noninvasive imaging modalities, blood flow measurements, and neuroretinal function.

Allen also has a strong background in academia. Allen worked at Harvard Medical School as an Associate in Medicine for almost two decades.

In addition, they served as the Chief Science Officer at Joslin Technologies, where they acted as a scientific advisor and project manager for translational research projects with biopharma companies. Allen provided statistical analysis and prepared final reports for each project.

Furthermore, Allen was involved in cardiology research at Massachusetts General Hospital, specifically focusing on vascular injury and atherosclerotic plaque formation in Type II diabetes.

Overall, Allen Clermont has a diverse and extensive work history in pharmacology, diabetes research, and translational research.

Allen Clermont attended Worcester Polytechnic Institute from 1981 to 1988. During this time, they completed a Masters of Science (MS) degree in Biomedical Engineering, building upon their prior Bachelor's degree in Electrical Engineering.